US-based Vedanta Biosciences has raised $27 million in a Series C financing to investigate microbiome-derived therapies for several indications, including cancer and food allergy. Investors include the Bill & Melinda Gates Foundation, Bristol-...
Original Article: PureTech's Vedanta raises $27m for microbiome research